Cytotoxic T Lymphocyte Responses to Proteins Encoded by Heterologous Transgenes TransferredIn Vivoby Adenoviral Vectors
- 1 July 1997
- journal article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 8 (10) , 1207-1217
- https://doi.org/10.1089/hum.1997.8.10-1207
Abstract
Although replication-deficient adenovirus (Ad) vectors are efficient vehicles for in vivo gene transfer, persistence of expression of the Ad genome is limited in immunocompetent hosts by cellular immunity directed against the gene product of the vector. While most attention has been focused on cytotoxic T lymphocytes (CTL) directed against the low-level early and late Ad gene expression in the Ad vector-infected target cells, significant cellular immunity is likely also directed against the product of heterologous transgenes. To evaluate this concept, in vivo generation of CTL was evaluated in C57B1/6 and BALB/c mice with Ad vectors expressing a variety of heterologous transgenes, including Escherichia coli chloramphenicol acetyl transferase (CAT), beta-galactosidase (beta-Gal), cytosine deaminase, and human thrombopoietin (hTPO), with an Ad vector expressing no transgene ("null") as a control. Following intravenous administration of Ad vectors, spleen cells were harvested 2 weeks later, stimulated for 5 days with syngeneic cells infected with various Ad vectors, and then evaluated for CTL activity using 51Cr-release from syngeneic Ad vector-infected targets. In all cases, CTL directed against the heterologous transgene products was observed, although there were differences in the amounts of transgene-specific CTL. CTL directed against the transgene were also observed with other routes of administration, including intratracheal, subcutaneous, and intraperitoneal administration. These observations suggest that inclusion of a heterologous transgene in Ad vectors enhances the elimination of vector-infected cells, a circumstance that will be partially circumvented using autologous genes. For some applications, specific immune responses to products of transgenes delivered by Ad vectors might be exploited for therapeutic purposes.Keywords
This publication has 36 references indexed in Scilit:
- Circumvention of Anti-Adenovirus Neutralizing Immunity by Administration of an Adenoviral Vector of an Alternate SerotypeHuman Gene Therapy, 1997
- Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus–mediated transfer of the VLDL receptor geneNature Genetics, 1996
- Long‐term humoral and cellular immunity induced by a single immunization with replication‐defective adenovirus recombinant vectorEuropean Journal of Immunology, 1995
- In VivoAdenovirus-Mediated Gene Transfer of theEscherichia coliCytosine Deaminase Gene to Human Colon Carcinoma-Derived Tumors Induces Chemosensitivity to 5-FluorocytosineHuman Gene Therapy, 1995
- MHC class I-cestricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenovirusesImmunity, 1994
- Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosisNature Genetics, 1994
- Tolerance, Danger, and the Extended FamilyAnnual Review of Immunology, 1994
- Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectorsNature Genetics, 1993
- In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epitheliumCell, 1992
- Adenovirus-Mediated Transfer of a Recombinant α1-Antitrypsin Gene to the Lung Epithelium in VivoScience, 1991